If you have been reading about GHK-Cu and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-18. Numbers and descriptions here follow the published literature rather than marketing material.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
Analytical verification typically combines reversed-phase high-performance liquid chromatography with ultraviolet-visible detection. The copper complex absorbs visible light near 600–630 nm, giving a characteristic blue signal. Mass spectrometry confirms molecular mass and can detect free peptide or mismatched copper stoichiometry. Copper content is often measured independently by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. Purity, counterion identity, and residual solvents are additional quality-control parameters that methods may address.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For lyophilized solid; solutions are less stable |
| Common analytical method | RP-HPLC with UV detection | For peptide purity; copper quantified separately |
| Copper quantification | ICP-MS or atomic absorption | Determines metal content and stoichiometry |
| Aqueous stability | Hours to days at room temperature | Depends on pH, buffer, and chelators |
| Color in solution | Blue | Absorption near 600 nm indicates Cu(II) coordination |
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Quality specifications for research material commonly state peptide purity, copper stoichiometry, counter-ion identity, and residual water content. Frequent counter-ions include acetate and trifluoroacetate, which differ in mass and in their effect on solubility and handling. Whether batch-to-batch differences in reported responses trace to these parameters or to assay conditions remains an open question, since published comparisons rarely control for all of them at once. Independent verification therefore normally pairs a purity measurement with an elemental copper measurement on the same lot.
Practical handling notes centre on limiting exposure to water, oxygen, and repeated temperature cycling. Weighed powder is often equilibrated to room temperature before opening to avoid condensation on the solid. Working solutions are typically divided into single-use aliquots and frozen rather than stored refrigerated for long periods. Reported shelf lives vary widely between laboratories, and no single set of conditions is universally treated as a reference standard, which complicates direct comparison of published stability figures.
== External links == Dhanvantari S. "Molecular and Cellular Mechanisms of Glucagon Synthesis and Secretion". lawsonimaging.ca. Archived from the original on 29 September 2007. "PC1 Cleavage Sites". phoenixpeptide.com. Archived from the original on 28 December 2005. "GLP-1 is Derived From Proglucagon". medscape.com. "Pro-glucagon". PDBe-KB Aggregated Views of Proteins. Wellcome Genome Campus, Hinxton, Cambridgeshire: EMBL-EBI.
With the advent of size exclusion chromatography (SEC), MALS measurements began to be used in conjunction with an on-line concentration detector to determine absolute molar mass and size of sample fractions eluting from the column, rather than depending on calibration techniques. These flow mode MALS measurements have been extended to other separation techniques such as field flow fractionation, ion exchange chromatography, and reversed-phase chromatography. The angular dependence of light scattering data is shown below in a figure of mix of polystyrene spheres which was separated by SEC. The two smallest samples (farthest to the right) eluted last and show no angular dependence. The sample, second to the right shows a linear angular variation with the intensity increasing at lower scattering angles. The largest sample, on the left, elutes first and shows non-linear angular variation.
Peptide YY (PYY), also known as peptide tyrosine tyrosine, is a peptide that in humans is encoded by the PYY gene. Peptide YY is a short (36-amino acid) peptide released from cells in the ileum and colon in response to feeding. In the blood, gut, and other elements of periphery, PYY acts to reduce appetite; similarly, when injected directly into the central nervous system, PYY is also anorexigenic, i.e., it reduces appetite. Dietary fibers from fruits, vegetables, and whole grains, consumed, increase the speed of transit of intestinal chyme into the ileum, to raise PYY3-36, and induce satiety. Peptide YY cannot be produced as the result of enzymatic breakdown of crude fish proteins and ingested as a food product.
CYP1A2 (strongly) which metabolizes agomelatine, amitriptyline, caffeine, clomipramine, clozapine, duloxetine, haloperidol, imipramine, phenacetin, tacrine, tamoxifen, theophylline, olanzapine, etc. CYP3A4 (moderately) which metabolizes alprazolam, aripiprazole, clozapine, haloperidol, quetiapine, pimozide, ziprasidone, etc. CYP2D6 (weakly) which metabolizes aripiprazole, chlorpromazine, clozapine, codeine, fluoxetine, haloperidol, olanzapine, oxycodone, paroxetine, perphenazine, pethidine, risperidone, sertraline, thioridazine, zuclopenthixol, etc. CYP2C9 (moderately) which metabolizes nonsteroidal anti-inflammatory drugs, phenytoin, sulfonylureas, etc. CYP2C19 (strongly) which metabolizes clonazepam, diazepam, phenytoin, etc. CYP2B6 (weakly) which metabolizes bupropion, cyclophosphamide, sertraline, tamoxifen, valproate, etc. By so doing, fluvoxamine can increase serum concentration of the substrates of these enzymes. Fluvoxamine may also elevate plasma levels of olanzapine by approximately two times. Combined olanzapine and fluvoxamine, which may cause increased sedation, should be used cautiously and controlled clinically and by therapeutic drug monitoring to avoid olanzapine induced adverse effects and/or intoxication. The plasma levels of oxidatively metabolized benzodiazepines (e.g., triazolam, midazolam, alprazolam, and diazepam) are likely to be increased when co-administered with fluvoxamine.
Sources: en.wikipedia.org
Different views (also known as projections) of the chest can be obtained by changing the relative orientation of the body and the direction of the x-ray beam. The most common views are posteroanterior, anteroposterior, and lateral. In a posteroanterior (PA) view, the x-ray source is positioned so that the x-ray beam enters through the posterior (back) aspect of the chest and exits out of the anterior (front) aspect, where the beam is detected. To obtain this view, the patient stands facing a flat surface behind which is an x-ray detector. A radiation source is positioned behind the patient at a standard distance (most often 6 feet, 1,8m), and the x-ray beam is fired toward the patient. In anteroposterior (AP) views, the positions of the x-ray source and detector are reversed: the x-ray beam enters through the anterior aspect and exits through the posterior aspect of the chest. AP chest x-rays are harder to read than PA x-rays and are therefore generally reserved for situations where it is difficult for the patient to get an ordinary chest x-ray, such as when the patient is bedridden. In this situation, mobile X-ray equipment is used to obtain a lying down chest x-ray (known as a "supine film"). As a result, most supine films are also AP. Lateral views of the chest are obtained in a similar fashion as the posteroanterior views, except in the lateral view, the patient stands with both arms raised and the left side of the chest pressed against a flat surface.
== History == The syndrome is named after Edward Treacher Collins (1862–1932), the English surgeon and ophthalmologist who described its essential traits in 1900. In 1949, Adolphe Franceschetti and David Klein described the same condition on their own observations as mandibulofacial dysostosis. The term mandibulofacial dysostosis is used to describe the clinical features.
In March 2018 Sara Rojas and her team published their research on drug incorporation and delivery with various biocompatible MOFs other than CD-MOF-1 through simulated cutaneous administration. The group studied the loading and release of ibuprofen (hydrophobic) and aspirin (hydrophilic) in three biocompatible MOFs (MIL-100(Fe), UiO-66(Zr), and MIL-127(Fe)). Under simulated cutaneous conditions (aqueous media at 37 °C) the six different combinations of drug-loaded MOFs fulfilled "the requirements to be used as topical drug delivery systems, such as released payload between 1 and 7 days" and delivering a therapeutic concentration of the drug of choice without causing unwanted side effects. The group discovered that the drug uptake is "governed by the hydrophilic/hydrophobic balance between cargo and matrix" and "the accessibility of the drug through the framework". The "controlled release under cutaneous conditions follows different kinetics profiles depending on: (i) the structure of the framework, with either a fast delivery from the open structure MIL-100 or a slower drug release from the narrow 1D pore system of MIL-127 or (ii) the hydrophobic/hydrophilic nature of the cargo, with a fast (Aspirin) and slow (Ibuprofen) release from the UiO-66 matrix." Moreover, a simple ball milling technique is used to efficiently encapsulate the model drugs 5-fluorouracil, caffeine, para-aminobenzoic acid, and benzocaine. Both computational and experimental studies confirm the suitability of [Zn4O(dmcapz)3] to incorporate high loadings of the studied bioactive molecules.
=== Supreme Court of Masonic Justice === A commission of the High Chamber of the Grand Lodge, called the Masonic Judicial Commission, met regularly when the Grand Lodge was established, but by the 1920s, the Grand Lodge understood the need to create a more functional and structured system to decide Masonic Law. Around 1936, the Cuban Supreme Court of Masonic Justice was created. This court was "...composed of magistrates of established prestige and authority." Francisco Sánchez Curbelo, having served as the President of the Masonic Judicial Commission since 1923, was then appointed as the first serving President of the Supreme Court of Masonic Justice.
Funding: Inadequate financial support for training programs and research activities. Brain Drain: Migration of trained specialists to other countries in search of better opportunities. Infrastructure: Limited access to modern medical facilities and equipment in some training centers. Efforts are ongoing to address these issues through policy reforms, increased funding, and international collaborations.
Sources: en.wikipedia.org
== Early life and education == Phil S. Baran was born in Denville, New Jersey, on August 10, 1977, and grew up in Coral Springs, Florida. He was not a strong academic student in high school, but developed early interests in creative pursuits like role-playing games, computer programming, and Lego building. Encouraged by his chemistry teacher to experiment after school, Baran quickly channeled his creativity into crafting molecules. In 1995 he began a chemistry degree at New York University, and enthusiastically accepted David Schuster's offer to work in his lab, synthesizing compounds that linked C60 with porphyrins to make artificial photosynthetic systems. He received his BS in chemistry from New York University in 1997. He went on to earn his PhD from The Scripps Research Institute in 2001, under the supervision of K. C. Nicolaou, an experience he recalls was 'like hardcore Navy Seal training' and where he co-authored 30 papers in less than four years. He then pursued a postdoctoral fellowship in the laboratory of Nobel Laureate Elias James Corey at Harvard University who reflected on Baran's time in his lab, saying, "He had a phenomenal grasp of synthetic chemistry," and "felt that he could be a leader in his generation." Baran is married to Mariana Baran and has four children.
Disulfiram inhibits the enzyme acetaldehyde dehydrogenase, which in turn results in buildup of acetaldehyde, a toxic metabolite of ethanol with unpleasant effects. The medication or drug is commonly used to treat alcohol use disorder, and results in immediate hangover-like symptoms upon consumption of alcohol, this effect is widely known as disulfiram effect.
Azeliragon vTv Therapeutics (formerly TransTech Pharma) sponsored a Phase 3 clinical trial of their RAGE inhibitor Azeliragon (TTP488) for mild Alzheimer's disease. These trials were halted in 2018. RAP (Receptor Antagonist Peptide) RAP is a peptide-based inhibitor that functions by directly competing with RAGE ligands for binding, thereby inhibiting RAGE-mediated signaling. It has shown potential in reducing vascular inflammation and preventing atherosclerosis in experimental models. RAP's ability to block the RAGE-ligand interaction has made it a candidate for cardiovascular disease therapies, particularly those involving chronic inflammation. FPS-ZM1 FPS-ZM1 is a well-known small molecule inhibitor of RAGE, designed to cross the blood-brain barrier and effectively block RAGE signaling in the central nervous system. Studies have demonstrated that FPS-ZM1 significantly reduces neuroinflammation and β-amyloid accumulation in mouse models of Alzheimer's disease. By inhibiting RAGE, FPS-ZM1 aims to reduce oxidative stress and inflammation associated with neurodegenerative processes, showing promise in preclinical studies for treating Alzheimer's disease and other neuroinflammatory conditions.
=== A Word a Year === Since 2004, Susie Dent, an English lexicographer has published a column, "A Word a Year", in which she chooses a single word from each of the last 101 years to represent preoccupations of the time. Susie Dent notes that the list is subjective. Each year, she gives a completely different set of words. Since Susie Dent works for the Oxford University Press, her words of choice are often incorrectly referred to as "Oxford Dictionary's Word of the Year".
== Properties and structure == Thiophene is a colorless liquid at room temperature. The high reactivity of thiophene toward sulfonation is the basis for the separation of thiophene from benzene, which are difficult to separate by distillation due to their similar boiling points (4 °C difference at ambient pressure). Like benzene, thiophene forms an azeotrope with ethanol. The molecule is flat; the bond angle at the sulfur is around 93°, the C–C–S angle is around 109°, and the other two carbons have a bond angle around 114°. The C–C bonds to the carbons adjacent to the sulfur are about 1.34 Å, the C–S bond length is around 1.70 Å, and the other C–C bond is about 1.41 Å.
Sources: en.wikipedia.org
Peptide content is usually measured by reverse-phase high-performance liquid chromatography, while copper is measured by atomic spectroscopy. Mass spectrometry can confirm the peptide identity and detect copper adducts. Combining these methods gives a more complete picture.
pH, temperature, oxygen, light, and the presence of metal chelators all influence stability. Strong chelators can strip copper from the peptide, and reducing agents can change the copper oxidation state. Lyophilized solid stored cold and dry is generally more stable than aqueous solutions.
Purity is method-dependent because different techniques detect different impurities. A peptide purity value from HPLC does not describe copper content or the amount of free peptide. Reports should specify the analytical method and the ratio of copper to peptide.
Dry powder is typically stored frozen at −20 °C or lower, protected from moisture and light. Short-term working amounts may be kept refrigerated. Avoiding repeated temperature changes helps preserve the material.